Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 11/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3096037 | 0.85 | FKBP1A (0.74) | FKBP1ASMN1; SMN2MAPTPOLBKDM4E | |
| SCHEMBL13606473 | 0.84 | FKBP1A (0.72) | FKBP1ASMN1; SMN2MAPTPOLBKDM4E | |
| SCHEMBL12409096 | 0.84 | KDM4E (0.78) | FKBP1ASMN1; SMN2MAPTPOLBKDM4E | |
| SCHEMBL2712996 | 0.83 | FKBP1A (0.74) | FKBP1ASMN1; SMN2MAPTPOLBKDM4E | |
| SCHEMBL8320871 | 0.83 | ALDH1A1 (0.79) | FKBP1ASMN1; SMN2POLBKDM4EALDH1A1 | |
| SCHEMBL10272936 | 0.82 | FKBP1A (0.72) | FKBP1ASMN1; SMN2MAPTPOLBKDM4E | |
| SCHEMBL528448 | 0.82 | ALDH1A1 (0.72) | FKBP1ASMN1; SMN2MAPTPOLBKDM4E | |
| SCHEMBL10224026 | 0.81 | FKBP1A (0.65) | FKBP1ASMN1; SMN2MAPTPOLBKDM4E | |
| SCHEMBL4403140 | 0.81 | FKBP1A (0.67) | FKBP1ASMN1; SMN2MAPTPOLBKDM4E | |
| SCHEMBL12017407 | 0.81 | FKBP1A (0.67) | FKBP1ASMN1; SMN2MAPTPOLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2022-06-07 | — | — | US | disclosed |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2022-06-07 | — | — | US | disclosed |
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-11-10 | — | — | US | disclosed |
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-11-10 | — | — | US | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-10596172-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-03-24 | — | — | US | disclosed |
| US-10596172-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-03-24 | — | — | US | disclosed |
| EP-3549934-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Celgene CAR LLC (BM) | 2019-10-09 | — | — | EP | disclosed |
| EP-3549934-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Celgene CAR LLC (BM) | 2019-10-09 | — | — | EP | disclosed |
| US-20190192512-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-06-27 | — | — | US | disclosed |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2009158571-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS AND USES THEREOF (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009158571-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS AND USES THEREOF (US) | 2009-12-30 | — | — | WO | disclosed |
| US-7629340-B2 | N-(6-membered aromatic ring)-amido anti-viral compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-08 | — | — | US | disclosed |
| EP-1976829-A2 | N-(6-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. (US) | 2008-10-08 | — | — | EP | disclosed |
| US-20070265262-A1 | N-(6-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. | 2007-11-15 | — | — | US | disclosed |
| WO-2007070556-A2 | N-(6-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | ABCG2, CYP3A43, CYP3A5 | FKBP1A 1145/4885SMN1; SMN2 2352/4885MAPT 1888/4885 |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | FKBP1A 1145/4885SMN1; SMN2 2352/4885MAPT 1888/4885 |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | FKBP1A 3059/4885SMN1; SMN2 4194/4885MAPT 3269/4885 |
| US-20190192512-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | FKBP1A 1145/4885SMN1; SMN2 2352/4885MAPT 1888/4885 |
| US-20070265262-A1 | N-(6-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | ZC3HAV1, HAVCR2, ZC3HAV1L | FKBP1A 3287/4885SMN1; SMN2 1109/4885MAPT 1728/4885 |
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | ABL1, DCK, ERBB2 | FKBP1A 2783/4885SMN1; SMN2 2891/4885MAPT 2723/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | FKBP1A 2792/4885SMN1; SMN2 986/4885MAPT 438/4885 |
| US-10596172-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | FKBP1A 3059/4885SMN1; SMN2 4194/4885MAPT 3269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.